CL2016003290A1 - Tratamiento de hipertrigliceridemia severa. - Google Patents
Tratamiento de hipertrigliceridemia severa.Info
- Publication number
- CL2016003290A1 CL2016003290A1 CL2016003290A CL2016003290A CL2016003290A1 CL 2016003290 A1 CL2016003290 A1 CL 2016003290A1 CL 2016003290 A CL2016003290 A CL 2016003290A CL 2016003290 A CL2016003290 A CL 2016003290A CL 2016003290 A1 CL2016003290 A1 CL 2016003290A1
- Authority
- CL
- Chile
- Prior art keywords
- treatment
- severe hypertriglyceridemia
- severe
- hypertriglyceridemia
- hypertrigliceridemia
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4192—1,2,3-Triazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/075—Ethers or acetals
- A61K31/085—Ethers or acetals having an ether linkage to aromatic ring nuclear carbon
- A61K31/09—Ethers or acetals having an ether linkage to aromatic ring nuclear carbon having two or more such linkages
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
- A61K31/202—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids having three or more double bonds, e.g. linolenic
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4406—Non condensed pyridines; Hydrogenated derivatives thereof only substituted in position 3, e.g. zimeldine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Cosmetics (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201462017444P | 2014-06-26 | 2014-06-26 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CL2016003290A1 true CL2016003290A1 (es) | 2017-09-08 |
Family
ID=53511030
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CL2016003290A CL2016003290A1 (es) | 2014-06-26 | 2016-12-22 | Tratamiento de hipertrigliceridemia severa. |
Country Status (16)
| Country | Link |
|---|---|
| US (1) | US20150374649A1 (enExample) |
| EP (1) | EP3160458A1 (enExample) |
| JP (1) | JP2017519028A (enExample) |
| KR (1) | KR20170020514A (enExample) |
| CN (1) | CN106470675A (enExample) |
| AU (1) | AU2015279905A1 (enExample) |
| BR (1) | BR112016028918A2 (enExample) |
| CA (1) | CA2951280A1 (enExample) |
| CL (1) | CL2016003290A1 (enExample) |
| EA (1) | EA201790091A1 (enExample) |
| HK (1) | HK1231380A1 (enExample) |
| IL (1) | IL249757A0 (enExample) |
| MX (1) | MX2016017081A (enExample) |
| PH (1) | PH12016502415A1 (enExample) |
| SG (1) | SG11201610243YA (enExample) |
| WO (1) | WO2015200580A1 (enExample) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| LT3119384T (lt) | 2014-03-20 | 2018-11-26 | Cymabay Therapeutics, Inc. | Intrahepatinių cholestazinių ligų gydymas |
| US10272058B2 (en) | 2014-03-20 | 2019-04-30 | Cymabay Therapeutics, Inc. | Treatment of intrahepatic cholestatic diseases |
| CN106163508A (zh) | 2014-04-11 | 2016-11-23 | 西玛贝医药公司 | Nafld和nash的治疗 |
| US10512622B2 (en) | 2017-07-14 | 2019-12-24 | Cymabay Therapeutics, Inc. | Treatment of intrahepatic cholestatic diseases |
| CA3085951C (en) * | 2017-12-21 | 2022-10-11 | Kowa Company, Ltd. | Methods of treatment of hypertriglyceridemia |
| US20210145775A1 (en) | 2019-11-14 | 2021-05-20 | Cymabay Therapeutics, Inc. | Treatment of intestinal barrier dysfunction and associated diseases |
| US20210145774A1 (en) | 2019-11-14 | 2021-05-20 | Cymabay Therapeutics, Inc. | Treatment of alcoholic liver disease |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SG145752A1 (en) | 2003-09-19 | 2008-09-29 | Janssen Pharmaceutica Nv | 4-((phenoxyalkyl)thio)-phenoxyacetic acids and analogs |
| JO3006B1 (ar) * | 2005-09-14 | 2016-09-05 | Janssen Pharmaceutica Nv | املاح ليسين مبتكرة من مشتقات حامض 4-((فينوكسي الكيل)ثيو) فينوكسي الخليك |
| SG183529A1 (en) * | 2010-03-30 | 2012-10-30 | Novartis Ag | Uses of dgat1 inhibitors |
-
2015
- 2015-06-25 HK HK17105013.3A patent/HK1231380A1/zh unknown
- 2015-06-25 BR BR112016028918A patent/BR112016028918A2/pt not_active Application Discontinuation
- 2015-06-25 WO PCT/US2015/037596 patent/WO2015200580A1/en not_active Ceased
- 2015-06-25 KR KR1020177002016A patent/KR20170020514A/ko not_active Withdrawn
- 2015-06-25 JP JP2016575073A patent/JP2017519028A/ja not_active Withdrawn
- 2015-06-25 MX MX2016017081A patent/MX2016017081A/es unknown
- 2015-06-25 EA EA201790091A patent/EA201790091A1/ru unknown
- 2015-06-25 CN CN201580033722.XA patent/CN106470675A/zh active Pending
- 2015-06-25 CA CA2951280A patent/CA2951280A1/en not_active Abandoned
- 2015-06-25 AU AU2015279905A patent/AU2015279905A1/en not_active Abandoned
- 2015-06-25 US US14/749,934 patent/US20150374649A1/en not_active Abandoned
- 2015-06-25 EP EP15734013.4A patent/EP3160458A1/en not_active Withdrawn
- 2015-06-25 SG SG11201610243YA patent/SG11201610243YA/en unknown
-
2016
- 2016-12-02 PH PH12016502415A patent/PH12016502415A1/en unknown
- 2016-12-22 CL CL2016003290A patent/CL2016003290A1/es unknown
- 2016-12-25 IL IL249757A patent/IL249757A0/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| PH12016502415A1 (en) | 2017-02-27 |
| MX2016017081A (es) | 2017-05-01 |
| SG11201610243YA (en) | 2017-01-27 |
| WO2015200580A1 (en) | 2015-12-30 |
| BR112016028918A2 (pt) | 2017-08-22 |
| CN106470675A (zh) | 2017-03-01 |
| HK1231380A1 (zh) | 2017-12-22 |
| KR20170020514A (ko) | 2017-02-22 |
| EP3160458A1 (en) | 2017-05-03 |
| IL249757A0 (en) | 2017-02-28 |
| EA201790091A1 (ru) | 2017-07-31 |
| JP2017519028A (ja) | 2017-07-13 |
| US20150374649A1 (en) | 2015-12-31 |
| AU2015279905A1 (en) | 2017-02-02 |
| CA2951280A1 (en) | 2015-12-30 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CL2016003290A1 (es) | Tratamiento de hipertrigliceridemia severa. | |
| CL2016002517A1 (es) | Uso de ácido r-2-4-2-etoxi-3-4-trifluormetilfenoxipropil-tio-2-metilfenoxi acético o una sal del mismo en la fabricación de un medicamento para tratar una condición que es una enfermedad de hígado graso no alcohólico o esteatohepatitis no alcohólica. | |
| CL2016001215A1 (es) | Tratamiento de hipercolesterolemia familiar homocigota. | |
| CL2016001458A1 (es) | Derivado de sulfonamida o sales de adición de ácido farmaceuticamente aceptables del mismo. | |
| UY36315A (es) | COMPUESTOS NOVEDOSOS ANTAGONISTAS DE INTEGRINA avß6. | |
| HUE051071T2 (hu) | Kannabidiol felhasználása gumós szklerózis komplex kezelésére | |
| CR20140231A (es) | Derivados de ácido benzotiazol-6-il acético y su uso para tratar una infección por vih | |
| EP3960735C0 (en) | QUINAZOLINE DERIVATIVES USED TO TREAT HIV | |
| CL2016002971A1 (es) | Combinación. | |
| CR20150418A (es) | Compuestos de tetrahidropirrolotiazina | |
| SI3198033T1 (sl) | Uporaba panelov FGRF-mutantnih genov pri identificiranju rakavih pacientov, ki bodo odzivni na zdravljenje z zaviralcem FGRF | |
| ES2721001T3 (es) | Derivado de isoindolina, y composiciones y métodos para tratar una enfermedad neurodegenerativa | |
| PH12017500393A1 (en) | Pyrrolopyrimidines for use in influenza virus infection | |
| EA201790266A1 (ru) | Индолы для применения при инфекции, вызванной вирусом гриппа | |
| IL249663A0 (en) | Process for the preparation of substituted oxiranes and triazoles | |
| AR103680A1 (es) | Inhibidores selectivos de bace1 | |
| SI3157534T1 (sl) | Inhibitorji acetilholinesteraze za zdravljenje dermatoloških obolenj | |
| CY1122264T1 (el) | Ppar ενωσεις για χρηση στην αντιμετωπιση των ινωτικων νοσων | |
| GB201413826D0 (en) | Plasma treatment of an infected nail or infected skin | |
| EP3092013A4 (en) | Sterilization of topical antiseptic solutions | |
| MX367478B (es) | Tratamiento de enfermedades colestasicas intrahepaticas. | |
| EA201791174A1 (ru) | Антимикотическое соединение | |
| MX2018007296A (es) | Compuestos de isoindol. | |
| EA201790687A1 (ru) | Хинолинкарбоксамиды для применения в лечении множественной миеломы | |
| PL3164116T3 (pl) | Kompozycje musujące zawierające kokryształy części kwasowej |